Biomarker
Immune Age Signals
Summary
Umbrella biomarker-signal record covering IMM-AGE, iAge, IMMAX, sc-ImmuAging, and related immune-clock approaches as distinct research-stage signals. It keeps diagnostic, consumer-test, biological-age certainty, and clinical-utility claims out of scope.
Intelligence Take
Immune Age Signals is useful as a high-caution source-reviewed record because the field has credible human cohort, association, methods, and framework sources while carrying high overclaim risk. The right LongevityNext framing is trial-readiness and validation gaps, not consumer immune-age testing, diagnosis, clinical utility, biological-age certainty, or intervention guidance.
Evidence Basis
Peer-reviewed IMM-AGE, iAge, immune-clock, and validation-framework sources; FDA biomarker qualification process and status resources; field reviews on biomarker validation and clinical translation. Source freshness was reviewed again on 2026-07-09 for the cautious claims used here.
Limitations
The reviewed source set does not establish immune-age models as approved diagnostics, consumer testing uses, individualized clinical decision tools, validated surrogate endpoints, biological-age certainty measures, or clinical-utility measures. Models differ materially and should not be treated as interchangeable. Regulatory status should be rechecked before any future expanded use.
Umbrella biomarker-signal record covering IMM-AGE, iAge, IMMAX, sc-ImmuAging, and related immune-clock approaches as distinct research-stage signals. It compares model-development, association, and trial-readiness evidence while keeping diagnostic, consumer-test, and clinical-utility claims out of scope.